Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Andrew ArmstrongDaniel George

Abstract

Phosphatidylinositol-3-kinase (PI3K) and androgen receptor pathway activation is common in metastatic castration resistant prostate cancer (mCRPC). Buparlisib is an oral, pan-class I PI3 kinase inhibitor. This was a multisite single arm phase II trial of buparlisib 100 mg ± enzalutamide daily in men with mCRPC whose disease progressed on or who were not candidates for docetaxel. The primary end-point was the rate of radiographic/clinical progression-free survival (PFS) at 6 months. Thirty men were accrued: 67% post-docetaxel; median prostate specific antigen (PSA) was 70 ng/dl, 83% had ≥4 prior therapies for mCRPC; 43% received concurrent enzalutamide. The final 6 month PFS rate was estimated to be 10% (95% confidence interval 2.5-23.6%). Median PFS was 1.9 months and was 3.5 months with concurrent enzalutamide. Median overall survival was 10.6 months. Concurrent enzalutamide led to a five-fold reduction in buparlisib concentrations. PSA declines were observed in 23%; no patients achieved a ≥50% decline, and no radiographic responses were observed. Severe adverse events occurred in four men including respiratory infection and multi-organ failure, urinary tract obstruction, confusion and one seizure in the setting of a new centr...Continue Reading

Citations

Feb 21, 2018·Nature Reviews. Urology·Tamara JamaspishviliTamara L Lotan
Jul 10, 2019·The EMBO Journal·Margit BleijsJarno Drost
Oct 5, 2019·Expert Review of Hematology·Ramona WullenkordGeorg Lenz
Nov 28, 2018·Nature Communications·Luke RussellBalveen Kaur
Feb 26, 2019·Prostate Cancer and Prostatic Diseases·Nicholas G NickolsMatthew B Rettig
Jun 2, 2020·American Society of Clinical Oncology Educational Book·Benedito A CarneiroRahul Aggarwal
Jul 21, 2017·Genes & Development·Étienne Audet-WalshVincent Giguère
Jul 13, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Emily W WrightMark E Welker
Jan 10, 2019·Evidence-based Complementary and Alternative Medicine : ECAM·Meng-Yao SunQing-Feng Tang
Feb 21, 2019·Molecular Cancer·Jing YangXiawei Wei
Jul 6, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ronald A NelsonMark E Welker
Jul 8, 2020·International Journal of Molecular Sciences·Boris Y ShorningHelen B Pearson
Dec 19, 2017·Investigational New Drugs·Olivier MirRaphaël Gaillard
May 3, 2020·Prostate Cancer and Prostatic Diseases·Milly J McAllisterJoanne Edwards
Nov 23, 2019·International Journal of Molecular Sciences·Petra Hillmann, Doriano Fabbro
Sep 27, 2018·Molecular & Cellular Oncology·Vaishali JayashankarAimee L Edinger
Sep 13, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tian ZhangAndrew J Armstrong
Sep 12, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Konrad H StopsackMassimo Loda
Dec 24, 2019·Seminars in Cancer Biology·Devesh TewariAnupam Bishayee
Sep 10, 2020·European Urology·David T Miyamoto, Richard J Lee
Oct 28, 2020·Cells·Daniel J TurnhamHelen B Pearson
Mar 7, 2021·Cancers·Amaal Ali, George Kulik
Aug 27, 2021·Clinical Genitourinary Cancer·Jason ChamMunveer Bhangoo
May 4, 2020·Biochimica Et Biophysica Acta. Molecular Cell Research·Luca BragliaSandra Marmiroli
Dec 18, 2021·Signal Transduction and Targeted Therapy·Yan HeBin Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.